03/18/23 7:00 AMNasdaq : ARQT clinical trialhigh shortArcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual MeetingNew INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream 0.15% Rapid and significant improvements were achieved including individuals reaching a 75% reduction of Eczema Area and Severity IndexRHEA-AIneutral
03/09/23 8:00 AMNasdaq : ARQT conferenceshigh shortArcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual MeetingLate breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitis New national survey insights depicting disease burden, path to diagnosis and treatment patterns for seborrheic dermatitis New clinical safety and efficacy data of topicalRHEA-AIneutral
03/03/23 4:00 PMNasdaq : ARQT high shortArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 27,550 restricted stockRHEA-AIvery positive
02/28/23 4:02 PMNasdaq : ARQT earningshigh shortArcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateAchieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growth Secured expanded commercial payer coverage for ZORYVE in plaque psoriasis with the second of the top three pharmacy benefitRHEA-AIvery positive
02/21/23 8:00 AMNasdaq : ARQT high shortArcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and AdolescentsSeborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United States If approved, roflumilast foam would be the first topical drug for seborrheic dermatitis with a new mechanism of action in over two decades In a pivotal Phase 3 trial, 80% ofRHEA-AIneutral
02/08/23 8:00 AMNasdaq : ARQT conferencesearningshigh shortArcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor ConferenceArcutis Biotherapeutics, Inc. (Nasdaq:RHEA-AIneutral
02/03/23 4:09 PMNasdaq : ARQT high shortArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 50,250 restricted stockRHEA-AIvery positive
01/14/23 4:00 AMNasdaq : ARQT clinical trialhigh shortArcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque PsoriasisDuring the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or almost clear was 10 months (40.1 weeks) Efficacy was consistent over time across all endpoints, and noRHEA-AIpositive
01/05/23 4:00 PMNasdaq : ARQT high shortArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 17,050 restricted stockRHEA-AIvery positive
12/19/22 8:00 AMNasdaq : ARQT high shortArcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of AgeRegulatory submission for the expanded indication is supported by data from two recently completed 4-week Maximal Usage Systemic Exposure (MUSE) studies in children ages 2 to 11 years with plaque psoriasis If approved, ZORYVE would be the first steroid-free topical phosphodiesterase-4 (PDE4)RHEA-AIneutral